Ignite Creation Date:
2025-12-24 @ 4:45 PM
Ignite Modification Date:
2026-02-02 @ 6:40 AM
Study NCT ID:
NCT05231850
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-02-09
First Post:
2022-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Colon Cancer | View |
Keywords: